Patents by Inventor Marie Brulliard

Marie Brulliard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11234445
    Abstract: The present invention relates to compositions and methods for modulating or detecting allergy in a subject. The invention may be used to reduce allergenicity of compositions, such as food products, or to stimulate immunogenicity of products, such as vaccines by removal of cationic proteins resulting from transcription infidelity. The invention may be used in any mammal such as human.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 1, 2022
    Assignee: GENCLIS
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard, Sandrine Jacquenet, Benoit Thouvenot, Olivier Roitel
  • Publication number: 20190116822
    Abstract: The present invention relates to compositions and methods for modulating or detecting allergy in a subject. The invention may be used to reduce allergenicity of compositions, such as food products, or to stimulate immunogenicity of products, such as vaccines. The invention may be used in any mammal such as human.
    Type: Application
    Filed: March 20, 2017
    Publication date: April 25, 2019
    Inventors: BERNARD BIHAIN, VIRGINIE OGIER, MARIE BRULLIARD, SANDRINE JACQUENET, BENOIT THOUVENOT, OLIVIER ROITEL
  • Patent number: 9068988
    Abstract: The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells hearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 30, 2015
    Assignee: TRANSMEDI SA
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard
  • Publication number: 20110097743
    Abstract: The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
    Type: Application
    Filed: December 15, 2008
    Publication date: April 28, 2011
    Applicant: TRANSMEDI SA
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard
  • Publication number: 20110053787
    Abstract: The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by identifying or measuring the levels of proteins that exhibits post-stop peptides in a sample from the subject. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
    Type: Application
    Filed: January 16, 2009
    Publication date: March 3, 2011
    Inventors: Marie Brulliard, Bernard Bihain